Connect with us

Hi, what are you looking for?

HR-positive/HER2-negative Breast Cancer Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

HR-positive/HER2-negative Breast Cancer Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
“DelveInsight Business Research LLP”
DelveInsight’s “HR-positive/HER2-negative Breast Cancer Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the HR-positive/HER2-negative Breast Cancer pipeline landscapes. It comprises HR-positive/HER2-negative Breast Cancer pipeline drug profiles, including clinical and non-clinical stage products.

DelveInsight’sHR-positive/HER2-negative Breast Cancer Pipeline Insight report provides comprehensive insights about key companies and pipeline drugs in the HR-positive/HER2-negative Breast Cancer pipeline landscapes. It comprises HR-positive/HER2-negative Breast Cancer pipeline drug profiles, including clinical and non-clinical stage products. It also includes the HR-positive/HER2-negative Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive HR-positive/HER2-negative Breast Cancer pipeline products.   

 

Some of the key takeaways of the HR-positive/HER2-negative Breast Cancer Pipeline Report  

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Jiangsu HengRui Medicine, Radius Pharmaceuticals, Immunomedics, Roche, Syndax Pharmaceuticals, Merck Sharp and Dohme, Merck Sharp and Dohme Corp./Eisai, Bayer, etc., are developing therapies for the treatment of HR-positive/HER2-negative Breast Cancer.

  • Emerging therapies such as SHR6390, Elacestrant (RAD1901), Sacituzumab govitecan, Ipatasertib and Venclexta, Entinostat, Pembrolizumab, Eribulin Mesylate, Radium-223 dichloride, are expected to have a significant impact on the  HR-positive/HER2-negative Breast Cancer market in the coming years.

  • The postmenopausal breast cancer market size within the 7MM was found to be USD 6,315.1 million in 2018.

  • The HR-positive/HER2-negative Breast Cancer market size shall increase during the forecast period 2021–2030.

  • Among the 7MM, the US accounts for 80.51% USD of the HR-positive/HER2-negative Breast Cancer market size in 2018. 

Get an overview of pipeline landscape @HR-positive/HER2-negative Breast Cancer Clinical Trials Analysis  

HR-positive/HER2-negative breast cancer is the commonest carcinoma and also accounts for a better percentage of all breast cancers. HR-positive cancer is typically treated with hormone therapies or a combination of hormone therapies with targeted therapy to assist stop tumor growth. 

HR-positive/HER2-negative Breast Cancer Emerging Drugs

  • SHR6390 by Jiangsu HengRui Medicine

  • Elacestrant (RAD1901) by Radius Pharmaceuticals

  • Sacituzumab govitecan by Immunomedics

  • Ipatasertib and Venclexta by Roche

  • Entinostat by Syndax Pharmaceuticals

  • Pembrolizumab by Merck Sharp and Dohme 

  • Eribulin Mesylate by Merck Sharp and Dohme Corp./Eisai   

  • Radium-223 dichloride by Bayer

  • And others.

Scope of HR-positive/HER2-negative Breast Cancer Pipeline Drug Insight

  • Coverage: Global 

  • Major Players: Jiangsu HengRui Medicine, Radius Pharmaceuticals, Immunomedics, Roche, Syndax Pharmaceuticals, Merck Sharp and Dohme, Merck Sharp and Dohme Corp./Eisai, Bayer, and others.

  • Pipeline Therapies: SHR6390, Elacestrant (RAD1901), Sacituzumab govitecan, Ipatasertib and Venclexta, Entinostat, Pembrolizumab, Eribulin Mesylate, Radium-223 dichloride, and others.

Table of Contents

1

HR-positive/HER2-negative Breast Cancer Report Introduction

2

HR-positive/HER2-negative Breast Cancer Executive Summary

3

HR-positive/HER2-negative Breast Cancer Overview

4

HR-positive/HER2-negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5

HR-positive/HER2-negative Breast Cancer Pipeline Therapeutics

6

HR-positive/HER2-negative Breast Cancer Late Stage Products (Phase II/III)

7

Advertisement. Scroll to continue reading.

HR-positive/HER2-negative Breast Cancer Mid Stage Products (Phase II)

8

HR-positive/HER2-negative Breast Cancer Early Stage Products (Phase I)

9

HR-positive/HER2-negative Breast Cancer Preclinical Stage Products

10

HR-positive/HER2-negative Breast Cancer Therapeutics Assessment

11

HR-positive/HER2-negative Breast Cancer Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

HR-positive/HER2-negative Breast Cancer Key Companies

14

HR-positive/HER2-negative Breast Cancer Key Products

15

HR-positive/HER2-negative Breast Cancer Unmet Needs

16 

HR-positive/HER2-negative Breast Cancer Market Drivers and Barriers

17

Advertisement. Scroll to continue reading.

HR-positive/HER2-negative Breast Cancer Future Perspectives and Conclusion

18

HR-positive/HER2-negative Breast Cancer Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @HR-positive/HER2-negative Breast Cancer Drugs Pipeline Report

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Written By

You may also like:

World

Nearly 200 nations start online negotiations Monday to validate a UN science report.

Life

Amid pushbacks against requiring coronavirus vaccinations for cruise ships and NFL players, there is now a new lobby for mandatory vaccination.

Life

Mary Simon, who on Monday became the first indigenous person to be named governor general of Canada, has fought to preserve her people's way...

Business

There is a lot in the news about cyberattacks and the risks. Ireland has a case in point, with personal data appearing on the...